Capricor Therapeutics is a clinical-stage biotech developing cell and exosome therapies, primarily for Duchenne muscular dystrophy, a rare muscle-wasting disease.
No revenue in 2025; 2024 revenue was USD 0.02B with a net loss of USD 0.04B. The company is pre-commercial, so no profit yet.
Potential moat from proprietary exosome technology and CAP-1002's clinical data, but competitors like Sarepta Therapeutics and Solid Biosciences are advancing DMD treatments. Moat is weak because no approved product and clinical-stage risks remain.
Key events, in time order
DJS Law Group files new class action alleging securities law violations, adding to prior suits
Earnings call reveals net loss and cash; FDA advisory committee vote unfavorable
FDA issues 483; LVEF p-value revised to 0.09 from 0.04; Lancet publishes final 1-year results
None yet
None yet
The user is tracking changes in their portfolio, noting a decrease in $CAPR. The post reflects a general portfolio update without specific commentary on $CAPR's performance or outlook.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
